

24 Department of Pediatrics
25 Division for Infectious Disease
26 Emory Vaccine Center
27 School of Medicine
28 Emory University
29 email: jwramme@emory.edu
30 Phone: 404-778-3265
31

32 **Abstract**

33 Since the emergence of SARS-CoV-2, research has shown that adult patients mount broad and
34 durable immune responses to infection. However, response to infection remains poorly studied in
35 infants/young children. In this study, we evaluated humoral responses to SARS-CoV-2 in 23
36 infants/young children before and after infection. We found that antibody responses to SARS-
37 CoV-2 spike antigens peaked approximately 30 days after infection and were maintained up to
38 500 days with little apparent decay. While the magnitude of humoral responses was similar to an
39 adult cohort recovered from mild/moderate COVID-19, both binding and neutralization titers to
40 WT SARS-CoV-2 were more durable in infants/young children, with Spike and RBD IgG
41 antibody half-life nearly 4X as long as in adults. The functional breadth of adult and
42 infant/young children SARS-CoV-2 responses were comparable, with similar reactivity against
43 panel of recent and previously circulating viral variants. Notably, IgG subtype analysis revealed
44 that while IgG1 formed the majority of both adults' and infants/young children's response, IgG3
45 was more common in adults and IgG2 in infants/young children. These findings raise important
46 questions regarding differential regulation of humoral immunity in infants/young children and
47 adults and could have broad implications for the timing of vaccination and booster strategies in
48 this age group.

49

50 **Keywords**

51 Infants, Antibody Response, Durability, SARS-CoV-2, Variants

52

53

54

55 **Introduction**

56 More than three years since the SARS-CoV-2 virus was first detected in humans, it continues to
57 cause severe morbidity and mortality worldwide (1, 2). Durable immune responses against
58 SARS-CoV-2 are crucial for prevention of severe disease and for protection against the
59 continuously emerging viral variants (3). The breadth and durability of the immune response has
60 been extensively studied following infection, as well as after primary and booster series of
61 vaccination, in both adults and older children (4-10). However, the immune response following
62 SARS-CoV-2 infection in infants and very young children remains poorly understood.

63 Although approximately one fourth of infants infected with SARS-CoV-2 are asymptomatic and
64 there are few reported deaths, severe COVID-19 is more common in young infants as compared
65 to older children (11-13). The immune system of infants starts to develop in the first few months
66 after delivery (14). Very little is known about how the immature immune system of an infant or
67 young child reacts to SARS-CoV-2 infection, and how the infection in those children in turn
68 impacts the development of the immune system. Even less is known about the durability of
69 immunity, given the difficulty of designing and executing multi-sample longitudinal studies in
70 these age groups. Thus, evaluation of the initial magnitude and the long-term durability of
71 infection-induced immune responses in infants/young children is critical. Moreover, a deeper
72 understanding of the breadth of humoral immune responses against continuously emerging viral
73 variants in infants/young children is vital for optimizing the timing of current vaccination
74 strategies in this age group (15, 16).

75 In this study, we present findings from the IMPRINT study; a prospective, longitudinal
76 birth cohort of influenza and SARS-CoV-2 infection and vaccination in early life conducted at
77 Cincinnati Children's Hospital Medical Center. IMPRINT participants provide weekly parent-

78 administered mid-turbinate nasal swabs, allowing for real-time identification of SARS-CoV-2
79 infected infants and young children. Multiple blood samples were obtained from these infants
80 and children over a period of up to 500 days after their initial SARS-CoV-2 positive swab. This
81 pediatric cohort was then compared to an adult cohort on which we have previously reported,
82 which collected blood samples from patients with PCR confirmed SARS-CoV-2 infection that
83 were followed for up to 350 days post infection (5). Herein we report that while the initial
84 magnitude of the SARS-CoV-2 specific antibody response in adults and infants/young children
85 was comparable, the titers in our infant cohort were maintained over the study period, while in
86 adults the titers declined with a half-life of 180 days (as previously reported by us and others) (5,
87 17, 18). Despite this major difference in terms of durability of humoral immunity, the functional
88 breadth of these responses was similar in adults and infants/young children, since the breadth of
89 reactivity against a panel of viral variants was essentially identical between these groups. Our
90 findings show significant differences in the maintenance of antibody responses in adults and
91 infants/young children and suggest that booster vaccination scheduling strategies in
92 infants/young children may need further evaluation.

93

94 **Results**

95

96 **Study cohort**

97 We included a total of 23 infants/young children and 19 adults in the study cohort. The
98 infants/young children, recruited at Cincinnati Children's Hospital, were followed since birth and
99 up to 500 days after their first positive PCR result for SARS-CoV-2. The COVID-19 confirmed
100 adult patients were previously enrolled in our longitudinal study of COVID-19 immune

101 durability (5), and followed for up to 350 days post-infection. Of the adults, a majority (84 %)
102 were non-hospitalized, and none had severe symptoms. Infants/young children were infected
103 during April 2020 – January 2022, and adults were infected during March – April 2020
104 (**Supplementary Figure 1**) (19, 20). The demographics and baseline characteristics of these
105 cohorts are described in **Table 1**. The infant cohort was 57 % females and 43 % males and
106 between 40 and 1441 days old (median age, 249 days). The adult cohort was 53 % females and
107 47 % males and between 20 and 77 years (median, 54 years).

108

109 **Durable antibody responses in infants/young children after SARS-CoV-2 infection.**

110 The magnitude and durability of antibody responses after SARS-CoV-2 infection have not been
111 carefully studied in infants/young children. Here we evaluated the longitudinal plasma antibody
112 responses against several SARS-CoV-2 antigens (Spike, RBD and NTD) pre-infection, during
113 acute infection, and following recovery in 23 SARS-CoV-2 infected infants and young children
114 using the Meso Scale Discovery electrochemiluminescence multiplex assay (MSD). All
115 infants/young children exhibited measurable IgG and IgA responses against Spike, RBD, and
116 NTD after infection, while IgM responses were negligible not only prior to infection, but also at
117 acute infection and convalescence stages in most individuals (data not shown). Pre-infection
118 levels of IgG and IgA against SARS-CoV-2 spike (**Figure 1A and D**), spike receptor binding
119 domain (RBD) (**Figure 1B and E**), and spike N-terminal domain (NTD) (**Figure 1C and F**)
120 were below the limit of detection, excluding an impact by maternal antibodies. The SARS-CoV-
121 2-specific IgG and IgA levels increased rapidly during acute infection, with subjects generating
122 detectable antibody responses as early as day four and peaking approximately 30 days post-

123 infection. The antibody titers were maintained following recovery for up to 500 days after the
124 positive PCR test with little apparent decay.

125

126 **SARS-CoV-2 infection results in increased antibody titers against the epidemic**
127 **coronaviruses MERS-CoV and SARS-CoV-1 in infants/young children**

128 We further evaluated the IgG antibody titers against the epidemic coronaviruses SARS-CoV-1
129 and MERS-CoV spike protein. The IgG binding antibody titers against both SARS-CoV-1 and
130 MERS-CoV spike protein increased during the acute phase of SARS-CoV-2 infection. IgG titers
131 peaked approximately 30 days post-infection and were maintained with little to no apparent
132 decay for up to 500 days post infection. (**Figure 2A**). Given that none of the infants/young
133 children could have been exposed to these coronaviruses, the increase in the IgG antibodies most
134 likely represents cross-reactive antibodies directed to SARS-CoV-2 spike epitopes which are
135 largely conserved between SARS-CoV-1, MERS-CoV and SARS-CoV-2 (21). This shows a
136 heightened immunity to the epidemic coronaviruses upon SARS-CoV-2 infection in
137 infants/young children.

138

139 **Pre-existing IgG antibody titers against the seasonal β -coronaviruses HKU1 and OC43**
140 **spike protein do not impact antibody responses after SARS-CoV-2 infection.**

141 It has been postulated that pre-existing antibody responses against seasonal beta-coronaviruses
142 might impact the responses against SARS-CoV-2. Since we had access to pre-infection samples
143 for this cohort, we next evaluated the IgG binding antibody response to the common human
144 coronaviruses HKU1 and OC43 in the pre-infection, acute infection, and convalescent plasma
145 samples from 23 SARS-CoV-2 infected infants/young children using the MSD assay. Overall,

146 IgG titers against the spike proteins of HKU1 and OC43 were largely unaffected by the SARS-
147 CoV-2 infection (**Figure 2B**). More importantly, post-infection titers against the SARS-CoV-2
148 spike protein showed no correlation to the baseline (pre-infection) titers against the HKU1 and
149 OC43 spike protein (**Figure 2C**) indicating that the level of pre-existing antibodies against
150 common human coronaviruses did not impact the anti-SARS-CoV-2 antibody response
151 following infection in infants and young children.

152

153 **Infants and young children show a more durable binding antibody response upon SARS-**
154 **CoV-2 infection as compared to adults.**

155 An important aspect of serological immunity is the durability of protection induced by infection.
156 To compare how the durability of antibody responses in infants/young children may differ from
157 that in adults, we compared these results to a cohort of adult patients on which we have
158 previously reported (5). The IgG responses to SARS-CoV-2 spike, RBD and NTD in infants and
159 young children were found to show minimal to no decay over time, with an estimated half-life of
160 800 (95 % confidence interval [95 % CI] [222, ∞]), 775 (95 % CI [263, ∞]), and 828 (95 % CI
161 [299, ∞]) days respectively, as estimated by the exponential decay model (**Figure 3A-C**). In
162 contrast, IgG antibodies specific to SARS-CoV-2 spike, RBD and NTD in adults were found to
163 decay much faster, with an estimated half-life of 187 (95 % CI [141, 281]), 178 (95 % CI [134,
164 264]), and 204 (95 % CI [149, 323]) days, respectively (**Figure 3E, 3F, and 3G**). We also
165 calculated the antibody decay using the power law decay model, which assumes that decay rates
166 decrease over time (5). The half-lives estimated by the power law model at day 150 for IgG
167 antibodies binding to SARS-CoV-2 spike, RBD, and NTD in the infants/young children were
168 1964 (95 % CI [204, ∞]), 2986 (95 % CI [492, ∞]), and 14190 (95 % CI [192, ∞]) days,

169 respectively. The longer half-lives as estimated by the power law model indicate that the decay
170 rate of the IgG antibodies declines over time, and that the concentration of the antibodies starts to
171 stabilize. In the adults, the half-lives of the IgG antibodies binding to spike, RBD and NTD, as
172 estimated by the power law model at day 150, were 405 (95 % CI [250, 915]), 356 (95 % CI
173 [228, 738]), and 450 (95 % CI [268, 1128]) days respectively.

174 As we have reported earlier in adults (5), anti-nucleocapsid IgG antibodies were found to
175 decline more rapidly compared to antibodies to other SARS-CoV-2 antigens. Interestingly, we
176 observed a similar fast decay in infants/young children, with the decay rate not statistically
177 different between the two groups ($p = 0.77$ for the exponential decay model and $p = 0.9$ for the
178 power law decay model, the Wald test). The half-lives of IgG antibodies binding to nucleocapsid
179 protein in infants/young children as calculated by the exponential and power law models were
180 116 (95 % CI [80, 216]), and 139 (95 % CI [83, 388]) days respectively (**Figure 3D**). The half-
181 lives of IgG antibodies binding to nucleocapsid protein in adults as calculated by the exponential
182 and power law models were 83 (95 % CI [73, 96]), and 116 (95 % CI [97, 144]) days respectively
183 (**Figure 3H**). Taken together, these results suggest that infants and young children show a more
184 durable binding antibody response to spike protein antigens and comparable durability of binding
185 antibody response to nucleocapsid protein upon SARS-CoV-2 infection as compared to adults.

186

187 **Infants/young children and adults show differences in IgG subclass distribution after**
188 **SARS-CoV-2 infection.**

189 To better understand the infection-induced humoral response in infants and young children and
190 to evaluate potential differences with the adult response, we next tested the anti-spike IgG
191 subclasses usage in a subset of samples representing early (30 – 140 days post infection) and late

192 (250 – 375 days post infection) time points following infection (**Figure 4A**). The IgG responses
193 can be further categorized into IgG1, IgG2, IgG3 and IgG4 antibody responses. Each of these
194 subclasses have unique properties and effector functions that are driven by the Fc portion of the
195 antibody molecule (22). Thus, we sought to characterize the IgG subclass usage of the SARS-
196 CoV-2 antibody response. IgG1 was found to be the most dominant subclass in both
197 infants/young children and adults, generating titers of 1 – 100 $\mu\text{g/mL}$ in both infants/young
198 children and adults. However, we observed notable differences in the anti-spike IgG subclass
199 distribution. The second most prevalent IgG subclass in infants was IgG2, forming 1 – 10 $\mu\text{g/mL}$
200 of the anti-Spike IgG response. In contrast, adults were significantly more likely to produce IgG3
201 ($p=0.0294$) (**Figure 4B**). These differences were most apparent at early time points, as the titers
202 in adults dropped over time and titers in infants/young children maintained, confirming the
203 higher durability of the antibody response in infants/young children.

204

205 **Infants/young children generate more durable neutralizing antibody response against WT**
206 **SARS-CoV-2 as compared to adults.**

207 We next evaluated early and late time points in infants and adults following infection to assess
208 the magnitude and durability of neutralizing antibody to WT (WA1\2020) SARS-CoV-2 strain
209 (**Figure 5A**). The neutralizing antibodies were measured using a live virus focus reduction
210 neutralization (FRNT) assay. Infants/young children and adults showed comparable neutralizing
211 antibody titers against WT SARS-CoV-2 at the early post-infection time point, with median
212 neutralizing antibody titers of 125 and 128 in infants/young children and adults, respectively.
213 73% of infants/young children and 68% of adults showed neutralizing antibody titer above the
214 limit of detection (> 20). In contrast, at the late time point infants/young children showed a

215 significantly higher neutralizing antibody response against WT SARS-CoV-2 as compared to the
216 adults, with the median neutralizing antibody titers of 131 in infants/young children and 22 in
217 adults ($p = 0.0151$). Furthermore, at the later time point 100% of infants/young children
218 registered neutralizing antibody titer above the limit of detection as opposed to only 58% of
219 adults.

220 Next, we assessed the relationship between anti-spike and anti-RBD antibody and
221 neutralizing antibody level in both infants and adults (**Figure 5B**). The spike and RBD IgG
222 levels were found to correlate significantly to the neutralizing antibody titer, at both early and
223 late time points, in infants/young children and adults ($p < 0.0001$) alike. The strong correlation of
224 anti-spike and anti-RBD titers with neutralization, combined with the observation of increased
225 durability of said titers, provides more evidence that infants/young children can maintain both
226 binding and neutralizing antibody titers for a much longer period as compared to adults.

227

228 **The antibody breadth against VOCs is similar in infants/young children and adults.**

229 To address potential functional differences in the antibody repertoire, we analyzed the ability to
230 bind and neutralize a panel of viral VOCs using early and late time point plasma samples from
231 infants/young children and adults. These analyses included the beta, delta, and omicron (BA.1)
232 variants. For the RBD IgG binding antibody response, infants/young children showed a 3-fold
233 reduction and adults showed a 4-fold reduction in binding to beta variant. Infants/young children
234 and adults showed a comparable 1 – 2-fold reduction in binding to delta variant. The reduction in
235 binding was more pronounced in case of Omicron (BA.1) variant with infants/young children
236 showing 17-fold reduction at early and 8-fold reduction at late time point, while adults showing
237 12-fold reduction at early and 9-fold reduction at late time point (**Figure 6A**). Similarly, for anti-

238 spike IgG titers, infants/young children and adults showed a 2-fold reduction in binding to beta
239 and 1 – 2-fold reduction in binding to delta variants. The reduction in binding was more evident
240 in case of Omicron (BA.1) variant. The infants/young children showed a 10-fold reduction in
241 binding at both early and late time points, while adults showed a 9-fold and 7-fold reduction in
242 banding at early and late time points respectively (**Supplementary Figure 2**).

243 Furthermore, both infants/young children and adults showed a significant reduction in
244 neutralizing ability against beta, delta and Omicron (BA.1) variants. The infants/young children
245 showed a 2 – 3-fold reduction in neutralization against beta and 1-fold reduction in neutralization
246 against delta variant. Adults showed a 2 – 5-fold reduction in neutralization against beta and 1-
247 fold reduction in neutralization against delta variant. The reduction in neutralization was even
248 more evident in case of Omicron (BA.1) variant. Infants/young children showed 6-fold and 7-
249 fold reduction, whereas adults showed 8-fold and 3-fold reduction in neutralization against
250 Omicron (BA.1) at early and late time points respectively (**Figure 6B**). Taken together, these
251 data suggest that the SARS-CoV-2 infected infants/young children and adults show a similar
252 breadth of antibody response against VOCs, with a significant reduction in the binding and
253 neutralizing ability against an Omicron (BA.1) variant.

254

255 **Discussion**

256

257 As SARS-CoV-2 establishes itself as an endemic infection, exposure in early childhood may
258 become routine. Therefore, it is critical to evaluate the magnitude and durability of immunity
259 following early life infection, which may help to predict whether early immunity is sufficient to
260 prevent new infections and severe disease later in life. Additionally, comparison of the immune

261 response to infection in infants/young children to that of adults provides essential context for
262 effective scheduling of primary and booster vaccinations across all age groups in view of
263 continuously emerging viral variants. Our study of longitudinally sampled infants/young children
264 is uniquely suited to evaluate these factors. These donors were followed with weekly nasal swabs
265 and timely blood collections beginning soon after birth, which allowed us to identify both
266 symptomatic and asymptomatic respiratory infections and evaluate the immune response both
267 prior to SARS-CoV-2 infection and longitudinally after the first infection in early life. In
268 addition, our cohort of longitudinally followed, non-severe adult COVID-19 patients enables a
269 direct comparison of the infection-induced immune response in these age groups. To address the
270 question of the durability of immune responses following infection, we evaluated the half-life of
271 antibodies to SARS-CoV-2 antigens. The most striking finding of our study was that the
272 infants/young children generated a much more durable binding and neutralizing antibody
273 response as compared to adults following SARS-CoV-2 infection. In adults, the half-life of IgG
274 binding antibodies was in the range of 178-204 days as estimated by the exponential decay
275 model. This finding is in line with the range our group and others have reported in the past (5,
276 17, 18). It is well established that the loss of binding titers results in a coordinated loss of
277 neutralization titer (**Figure 5A**) (16, 23-25), most likely due to the strong correlation between
278 spike and RBD binding titers and neutralization (**Figure 5B**) (11, 26), indicating that fraction of
279 anti-spike/RBD IgG is able to block SARS-CoV-2 entry into cells. The relatively rapid decline in
280 binding and neutralization titers in adults is one factor that drives the recommended frequency of
281 vaccine boosters. Therefore, it is a valuable insight that infants/young children showed a much
282 more durable antibody response with half-lives of 700 – 800 days, nearly four times that of
283 adults (**Figure 3**). Though the early and adult immune systems differ in a myriad of ways (27),

284 infants/young children were able to generate robust neutralization titers. Indeed, infants/young
285 children and adults produced neutralization titers comparable in magnitude early during the
286 response to infection. In contrast to the rapidly declining neutralization titers in adults, the
287 infants/young children did not exhibit significant reduction in neutralization titers at late time
288 points, highlighting the longer durability of immunity following infection in this age group.
289 These differences between infants/young children and adults could be due to different
290 immunological milieus during the induction of the responses during acute infection, which could
291 result in differences in the generation of long-lived plasma cells or be mediated by differences in
292 the ability of the infant and adult bone marrow to support the survival of long-lived SARS-CoV-
293 2 specific plasma cells. The mechanistic explanation for our findings requires further study.
294 Notably, the striking differences in the durability of binding antibody to SARS-CoV-2 S antigens
295 is not observed in regard to anti-nucleocapsid IgG. Infants/young children and adults exhibit a
296 comparable rapid decline of anti-nucleocapsid IgG antibodies. This suggests that anti-spike, -
297 RBD and -nucleocapsid humoral responses may be differentially regulated and implies that the
298 increased durability in infants/young children is not necessarily universal for every antigen. It is
299 possible that location, concentration, and/or availability of antigens differs during infection in
300 adults compared to infants/young children, and that exploring these differences may lead to
301 uncovering factors that could modulate durability of humoral immunity in adults. The spike
302 protein of SARS-CoV-2 is a critical target of mRNA vaccines (28, 29), and the higher durability
303 of spike-binding and neutralizing antibodies in infants/young children raise a possibility of
304 similar increased durability of the immune response to vaccination, which may further impact
305 booster scheduling in this age group. This cohort of donors, as well as peers who have not
306 experienced infection, will continue to be followed, allowing us to build on these results and

307 address important questions regarding durability of immune response to primary and booster
308 series of vaccination in infection-experienced and naïve children. Overall, these findings provide
309 important insight into the humoral immune response in very young children in a world in which
310 childhood SARS-CoV-2 infection may become endemic.

311 Our study also observed variability in the IgG subclass usage in response to infection in
312 infants/young children as compared to adults. As we have shown previously in adults (30), we
313 observed a predominance IgG1 antibodies in both infants/young children and adults. Indeed,
314 while IgG1 formed the most dominant subclass, adults and children differed in their secondary
315 subtype, showing significant contribution of IgG2 in infants/young children and IgG3 in adults.
316 IgG2 is known to be associated with neutralization and non-inflammatory response, and is
317 known to reduce the detrimental effect of antibody-dependent enhancement (ADE), whereas
318 IgG1, IgG3, and IgG4 are associated with both neutralization and ADE effects (31, 32). The
319 higher contribution of IgG2 antibodies in infants/young children may contribute to less severe
320 disease and fewer deaths in this age group as compared to adults. While subclass differences
321 were subtle, these findings may provide important clues for how the immune response to
322 infection is regulated in adults and infants/young children, and continued investigation may have
323 broader implications for future vaccine development that could target a specific subclass of
324 antibodies.

325 Another relevant question is whether pre-existing immunity against the commonly
326 circulating human coronaviruses (HKU1 and OC43) provides cross-protection against SARS-
327 CoV-2 infection? Although cross-reactivity and/or cross-protection between SARS-CoV-2 and
328 HCoV-229E has been reported (33-35), we found no evidence of a major impact of pre-existing
329 seasonal HCoV-229E titers on the magnitude or quality of SARS-CoV-2 responses in infants/young

330 children. Since virtually all adults have experienced infection with common human
331 coronaviruses and will therefore have pre-existing titers (5), the study of infants/young children
332 provides a unique opportunity to assess responses to SARS-CoV-2 without pre-existing
333 exposure. While this study could not measure protection, the pre-infection baseline titers of
334 HCoV's spike protein did not correlate with the SARS-CoV-2 spike convalescent IgG antibody
335 titers, suggesting pre-existing antibody titers did not result in an increased humoral response to
336 SARS-CoV-2. It is also evident from low to non-existent IgG and IgA titers against the SARS-
337 CoV-2 antigens observed in the pre-infection samples in the infants/young children, suggesting
338 that the SARS-CoV-2 infection and immune response is independent of the HCoV's serostatus.
339 This is in line with other studies done in older children and adults where the cross-protection by
340 HCoV's has not been reported (36, 37). These important observations again highlight the need for
341 vaccination against SARS-CoV-2 in infants/young children despite the pre-existing immunity
342 against seasonal beta-coronaviruses. However, likely due to the high degree of spike protein
343 conservation (21), we did find an increase in the IgG binding antibody titers against previous
344 endemic coronaviruses, MERS-CoV and SARS-CoV-1 upon SARS-CoV-2 infection in
345 infants/young children. This finding is consistent with other studies where SARS-CoV-1 titers
346 were found to increase upon SARS-CoV-2 infection and mRNA vaccination in adults (5, 38).
347 Taken together, these results may have implications for a broader strategy for vaccination
348 targeting multiple human beta-coronaviruses.

349 Despite the differences in durability, our study demonstrated a very similar breadth of
350 antibody repertoire in infants/young children and adults against VOCs such as beta, delta, and
351 omicron (BA.1). We found lower binding and neutralizing antibody titers against beta and delta
352 variants as compared to the WT in both infants/young children and adults, with differences being

353 most apparent in the beta variant. As expected, the largest differences were observed for the
354 omicron variant (BA.1). Prior SARS-CoV-2 infection in adults has shown to not confer cross-
355 protection against the omicron variant (39, 40) in adults, an observation that impacted the
356 approval of the bivalent booster. However, this has not been fully characterized in infants/young
357 children. As observed in adults, we found a marked reduction in binding and neutralizing
358 antibody titers against omicron (BA.1) variant in infants/young children. This underscores the
359 potential of this VOC to evade the infection-induced immune response and cause re-infections in
360 infants/young children even in light of their improved antibody durability. Booster vaccination
361 increases responses to omicron in adults (41), and may rescue lower responses in infants/young
362 children and may be necessary to protect from continuously emerging viral variants.

363 SARS-CoV-2 remains a global public health threat even after years of devastating
364 disturbances and loss. To date, vaccination remains the best possible strategy in the fight against
365 COVID-19. Thus, development of the booster vaccines that target evolving viral variants and
366 optimum scheduling of vaccinations are both important factors in preventing new cases and
367 progression to severe disease. A critical aspect for effective scheduling of vaccinations is
368 understanding how long immunity persists following infection in various age groups. Our study
369 demonstrated that infants/young children produce a significantly more durable antibody response
370 to SARS-CoV-2 S antigens following infection as compared to adults, a response that correlates
371 with extended neutralization, which may have implications for scheduling of vaccination and
372 boosters. In addition, we found that natural infection confers a similar breadth of antibody
373 repertoire in these disparate age groups, indicating a need for further study on the effect of
374 boosters for prevention of continuously evolving variants.

375

376 **Limitations of the study**

377 The major limitation of this study was the small cohort size which did not allow us to study the
378 sex related effects to the SARS-CoV-2 infection induced immune response in infants/young
379 children. Several reports have described notable differences in the immune response to COVID-
380 19 between males and females (42-45). Thus, it is possible that this could have impacted our
381 findings. However, while not fully powered to address this, we found no difference in the
382 immune response to SARS-CoV-2 infection in infants/young children comparing males and
383 females (data not shown). Future studies with larger number of infants/young children in the
384 study cohort would be needed to better address this question. In addition, while our study
385 compared an immune response to infection in infants/young children and adults, these donors
386 were infected at different times during the pandemic most likely with corresponding main
387 circulating viral variants. While it would have been interesting to compare the infants/young
388 children and adults matched with respect to time of infection, we did not have the longitudinally
389 followed matched donors to evaluate this. However, a similar breadth of antibody repertoire
390 against VOCs in infants/young children and adults highlight the relevance of our findings.

391

392 **Methods**

393

394 **Participant sample collection**

395 The enrolled infants/young children at Cincinnati children's hospital were part of a larger study
396 of influenza infection and vaccination in early life. The study population included infants/young
397 children who were followed since birth with weekly nasal swabs and twice weekly symptom
398 surveys to diagnose the respiratory infections and describe clinical presentations, respectively.

399 The blood and saliva samples were collected from these donors prior to and acutely after
400 influenza vaccination or infection and SARS-CoV-2 vaccination or infection with longitudinally
401 collected convalescent blood samples following these events. The Atlanta study population
402 included adult volunteers over the age 18 who were diagnosed with COVID-19 by a
403 commercially available SARS-CoV-2 PCR test. Informed consent was obtained from all
404 participants prior to conduct of study procedures. The participants provided a medical history of
405 co-morbidities, presentation of SARS-CoV-2 infection onset and disease course. The serial
406 peripheral blood samples were collected starting approximately 30 days after SARS-CoV-2
407 infection and thereafter at 3, 6, and 9 months. The participants were excluded if they were
408 immunocompromised, HIV positive, had active hepatitis B or C virus infection, used
409 immunosuppressive drugs for 2 weeks or more in the preceding 3 months, received blood
410 products or immunoglobulin 42 days prior to enrollment, received convalescent COVID-19
411 plasma, or were pregnant or breastfeeding.

412

413 **Viruses and cell lines**

414 VeroE6-TMPRSS2 cells were cultured as described previously (46) and used to propagate all
415 virus stocks. nCOV/USA_WA1\2020 (WA1), closely resembling the original Wuhan strain was
416 propagated from an infectious SARS-CoV-2 clone as described previously (47). The B.1.351
417 variant isolate was kindly provided by Dr. Andy Pekosz (John Hopkins University, Baltimore,
418 MD), was propagated once to generate a working stock (46). hCOV-19/USA/PHC658/2021
419 referred to as B.1.617.2 variant) was derived from nasal swab collected in May 2021 (48).
420 EPI_ISL_7171744 (BA.1) variant was propagated once to generate the working stock (49). All
421 variants were plaque purified on VeroE6-TMPRSS2 cells and propagated once in a 12-well plate

422 of confluent VeroE6-TMPRSS2 cells followed by expansion of the working stock in T175 flasks
423 on confluent VeroE6-TMPRSS2 cells. All viruses used in this study were deep sequenced and
424 confirmed as previously described (48).

425

426 **Multiplex electrochemiluminescence (ECLIA) Immunoassay**

427 The levels of IgG, and IgA antibodies were measured using the multiplex plates by Mesoscale
428 Discovery (MSD), following manufacturer's instructions. The V-PLEX Coronavirus Plate 1
429 (K15362U) were used to analyze the binding antibody responses against WT SARS-CoV-2 and
430 other human coronaviruses, while V-PLEX SARS-CoV-2 panel 24 (K15575U) and panel 26
431 (K15593U) were used to assess the binding antibody responses to additional VOC-derived spike
432 and RBD respectively. Briefly the plates were first blocked using the 5 % solution of Bovine
433 Serum Albumin (BSA) in 1X PBS and incubated at room temperature with shaking at 700 RPM
434 for at least 30 min. Following incubation, the plates were washed three times using 1X DPBS/
435 0.05 % Tween. The serum samples, diluted 1:5000 (for IgG), and 1:1000 (for IgA, and IgM),
436 were added and the plates were incubated at room temperature with shaking at 700 RPM for 2 h.
437 Following a wash, sulfo-tag anti-human detection antibody (IgG, IgA, IgM, IgG1 Fc, IgG2, Fc,
438 IgG3 Fc, or IgG4 Fc) were added, and the plates were incubated at room temperature with
439 shaking at 700 RPM for 1 h. After the subsequent wash, 150 uL/well of MSD Gold Read Buffer
440 B was added to the plates and the plates were read immediately on the MSD instrument to
441 measure the light intensity. The levels of the antibodies are reported as the arbitrary units/ mL
442 (AU/mL) or $\mu\text{g/mL}$ based on the normalization of the standard curve.

443

444

445 **Focus reduction neutralization assay**

446 The FRNT assays were performed as described previously (46, 48, 50). Briefly, the plasma
447 samples were diluted 3-fold in eight serial dilution in DMEM in duplicates, with an initial
448 dilution of 1:10 in a total volume of 60 μ L, followed by incubation with equal volume of
449 respective SARS-CoV-2 variant. The antibody-virus mixture was then added to VeroE6-
450 TMPRSS2 cells. After incubation, the antibody-virus mixture was removed and pre-warmed 0.85
451 % methylcellulose overlay was added to each well. After removal of the overlay, the cells were
452 fixed with 2 % paraformaldehyde in PBS. Following fixation, permeabilization buffer (0.1 %
453 BSA, Saponin in PBS) was added to the permeabilized cells. The cells were incubated with an
454 anti-SARS-CoV spike primary antibody directly conjugated to Alexafluor-647 (CR3022-
455 AF647). The foci were visualized on an ELISpot reader (CTL).

456

457 **Statistical analysis**

458 Mixed effects exponential and power law models implemented in Monolix (Monolix, Lixoft)
459 were used to analyze the waning of the antibody response (day 30 to day 500 in infants/young
460 children and day 30 to day 350 in adult donors). The exponential and power law models were
461 formulated as ordinary differential equations, $\frac{dAb}{dt} = -k \cdot Ab$ and $\frac{dAb}{dt} = -\frac{k}{t} \cdot Ab$, respectively,
462 with antibody at day 30 lognormally distributed and decay rate k normally distributed and with
463 lognormal multiplicative error. The data were analyzed using GraphPad Prism 9.5.0. The
464 antibody neutralization titers were quantified by counting number of foci for each sample using
465 the Viridot program. The neutralization titers were calculated as $[1 - (\text{average number of foci in}$
466 $\text{wells incubated with patient serum}) \div (\text{average number of foci in wells incubated with control}$
467 $\text{serum})]$. The correlation analyses to determine coefficient of determination (R^2), and

468 significance were performed by log transforming the binding and neutralization titers followed
469 by simple linear regression. The comparisons between groups were performed using unpaired
470 two-tailed t-test.

471

472 **Study approval**

473 The longitudinal IMPRINT influenza cohort study at Cincinnati Children's Hospital Medical
474 Center (Cincinnati, OH) and COVID-19 longitudinal cohort study at Emory University (Atlanta,
475 Georgia) began after receiving the Institutional Review Board approvals (IRB 2019-0629,
476 IRB00022371 respectively).

477

478 **Funding Details**

479 This work was supported in part by grants U01AI144673-02, 3U19AI057266-17S2, and
480 U54CA260563 from the National Institute of Allergy and Infectious Diseases (NIAID), National
481 Institutes of Health (NIH), and by the Oliver S. and Jennie R. Donaldson Charitable Trust,
482 Emory Executive Vice President for Health Affairs Synergy Fund award, the Georgia Research
483 Alliance, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and
484 Children's Healthcare of Atlanta, the Emory-UGA Center of Excellence for Influenza Research
485 and Surveillance (Atlanta, GA USA), and a Woodruff Health Sciences Center 2020 COVID-19
486 CURE Award.

487

488 **Author Contribution**

489 D.J. performed data acquisition, data curation and analysis, data visualization, and writing the
490 manuscript. L.E.N and V.Z. contributed to data curation and analysis, data visualization, writing

491 review and editing. A.M., K.M., and S.L contributed to investigation, data curation and analysis.
492 A.R.B. and K.S. provided clinical support, contributed to patient recruitment and clinical data
493 curation. G.M. and C.N. contributed to patient sample collection and paper review. R.A., E.J.A.,
494 M.A.S., M.S.S., and J.W. contributed to the conception and design of the study, writing and
495 editing of the manuscript, and obtaining study funding. All authors have read and accepted the
496 manuscript.

497

498 **Declaration of Interest**

499 MSS has served as an advisor for Ocugen and Moderna. E.J.A. has consulted for Pfizer, Sanofi
500 Pasteur, Janssen, and Medscape, and his institution receives funds to conduct clinical research
501 unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sonfi-
502 Pasteur, Janssen, and Micron. He also serves on data and safety monitoring boards for Kentucky
503 BioProcessing, Inc., and Sanofi Pasteur. His institution has also received funding from NIH to
504 conduct clinical trials of Moderna and Janssen COVID-19 vaccines. M.A.S. received funding
505 from CDC, Pfizer, Merck and Cepheid to study immune response to respiratory virus infections
506 and vaccinations.

507

508 **Acknowledgements**

509 We thank the participants and parents of infant donors for volunteering their time and efforts to
510 participate in this study. We also thank Christina Rostad and Sanjeev Kumar for critically
511 reviewing the manuscript. The graphical abstract was created using Biorender.com.

512 References

- 513 1. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Consortium C-GU, et al.
514 SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nat Rev*
515 *Microbiol.* 2023;21(3):162-77.
- 516 2. Zhou Y, Zhi H, and Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune
517 escape, and vaccine effectivity. *Journal of Medical Virology.* 2023;95(1):e28138.
- 518 3. Townsend JP, Hassler HB, Sah P, Galvani AP, and Dornburg A. The durability of natural
519 infection and vaccine-induced immunity against future infection by SARS-CoV-2. *Proc*
520 *Natl Acad Sci U S A.* 2022;119(31):e2204336119.
- 521 4. Mantus G, Nyhoff LE, Edara VV, Zarnitsyna VI, Ciric CR, Flowers MW, et al. Pre-existing
522 SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral
523 response to SARS-CoV-2 vaccination. *Cell Rep Med.* 2022;3(4):100603.
- 524 5. Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal
525 analysis shows durable and broad immune memory after SARS-CoV-2 infection with
526 persisting antibody responses and memory B and T cells. *Cell Rep Med.*
527 2021;2(7):100354.
- 528 6. Gilboa M, Regev-Yochay G, Mandelboim M, Indenbaum V, Asraf K, Fluss R, et al.
529 Durability of Immune Response After COVID-19 Booster Vaccination and Association
530 With COVID-19 Omicron Infection. *JAMA Netw Open.* 2022;5(9):e2231778.
- 531 7. Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung PK, et al. Reduced
532 Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines
533 Among Older Adults. *J Infect Dis.* 2022;225(7):1129-40.
- 534 8. Suthar MS, Arunachalam PS, Hu M, Reis N, Trisal M, Raeber O, et al. Durability of
535 immune responses to the BNT162b2 mRNA vaccine. *Med.* 2022;3(1):25-7.
- 536 9. Di Chiara C, Cantarutti A, Costenaro P, Dona D, Bonfante F, Cosma C, et al. Long-term
537 Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild
538 Infection. *JAMA Netw Open.* 2022;5(7):e2221616.
- 539 10. Gupta SL, Mantus G, Manning KE, Ellis M, Patel M, Ciric CR, et al. Loss of Pfizer
540 (BNT162b2) vaccine-induced antibody responses against the SARS-CoV-2 Omicron
541 variant in adolescents and adults. *Journal of virology.* 2022;96(17):e00582-22.
- 542 11. Goenka A, Halliday A, Gregorova M, Milodowski E, Thomas A, Williamson MK, et al.
543 Young infants exhibit robust functional antibody responses and restrained IFN-gamma
544 production to SARS-CoV-2. *Cell Rep Med.* 2021;2(7):100327.
- 545 12. O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al.
546 Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature.*
547 2021;590(7844):140-5.
- 548 13. Trevisanuto D, Cavallin F, Cavicchiolo ME, Borellini M, Calgaro S, and Baraldi E.
549 Coronavirus infection in neonates: a systematic review. *Arch Dis Child Fetal Neonatal Ed.*
550 2021;106(3):330-5.
- 551 14. Simon AK, Hollander GA, and McMichael A. Evolution of the immune system in humans
552 from infancy to old age. *Proc Biol Sci.* 2015;282(1821):20143085.

- 553 15. Sempowski GD, Saunders KO, Acharya P, Wiehe KJ, and Haynes BF. Pandemic
554 Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. *Cell*.
555 2020;181(7):1458-63.
- 556 16. Noval MG, Kaczmarek ME, Koide A, Rodriguez-Rodriguez BA, Louie P, Tada T, et al.
557 Antibody isotype diversity against SARS-CoV-2 is associated with differential serum
558 neutralization capacities. *Sci Rep*. 2021;11(1):5538.
- 559 17. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody
560 responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
561 *EBioMedicine*. 2021;71:103561.
- 562 18. Capetti AF, Borgonovo F, Mileto D, Gagliardi G, Mariani C, Lupo A, et al. One-year
563 durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown
564 prospective observational study one year durability of COVID-19 anti-spike IgG. *Journal*
565 *of Infection*. 2021;83(2):237-79.
- 566 19. Flores-Vega VR, Monroy-Molina JV, Jimenez-Hernandez LE, Torres AG, Santos-Preciado
567 JI, and Rosales-Reyes R. SARS-CoV-2: Evolution and Emergence of New Viral Variants.
568 *Viruses*. 2022;14(4).
- 569 20. Duong D. Alpha, Beta, Delta, Gamma: What's important to know about SARS-CoV-2
570 variants of concern? *CMAJ*. 2021;193(27):E1059-E60.
- 571 21. Bates TA, Weinstein JB, Leier HC, Messer WB, and Tafesse FG. Cross-reactivity of SARS-
572 CoV structural protein antibodies against SARS-CoV-2. *Cell reports*. 2021;34(7):108737.
- 573 22. Yates JL, Ehrbar DJ, Hunt DT, Girardin RC, Dupuis AP, 2nd, Payne AF, et al. Serological
574 analysis reveals an imbalanced IgG subclass composition associated with COVID-19
575 disease severity. *Cell Rep Med*. 2021;2(7):100329.
- 576 23. Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E, et
577 al. Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in
578 SARS-CoV-2 infection. *Cell Rep Med*. 2021;2(4):100228.
- 579 24. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of immune
580 responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat Commun*. 2021;12(1):1162.
- 581 25. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal
582 observation and decline of neutralizing antibody responses in the three months
583 following SARS-CoV-2 infection in humans. *Nat Microbiol*. 2020;5(12):1598-607.
- 584 26. Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M-L, et al.
585 Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a
586 fishery vessel outbreak with a high attack rate. *Journal of clinical microbiology*.
587 2020;58(11):e02107-20.
- 588 27. Pieren DKJ, Boer MC, and de Wit J. The adaptive immune system in early life: The shift
589 makes it count. *Front Immunol*. 2022;13:1031924.
- 590 28. Huang Q, Zeng J, and Yan J. COVID-19 mRNA vaccines. *J Genet Genomics*.
591 2021;48(2):107-14.
- 592 29. Hogan MJ, and Pardi N. mRNA Vaccines in the COVID-19 Pandemic and Beyond. *Annu*
593 *Rev Med*. 2022;73:17-39.
- 594 30. Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al.
595 Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. *Cell Rep*
596 *Med*. 2020;1(3):100040.

- 597 31. Andualem H, Kiros M, Getu S, and Hailemichael W. Immunoglobulin G2 Antibody as a
598 Potential Target for COVID-19 Vaccine. *Immunotargets Ther.* 2020;9:143-9.
- 599 32. Lu LL, Suscovich TJ, Fortune SM, and Alter G. Beyond binding: antibody effector
600 functions in infectious diseases. *Nat Rev Immunol.* 2018;18(1):46-61.
- 601 33. Fraley E, LeMaster C, Banerjee D, Khanal S, Selvarangan R, and Bradley T. Cross-reactive
602 antibody immunity against SARS-CoV-2 in children and adults. *Cell Mol Immunol.*
603 2021;18(7):1826-8.
- 604 34. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal
605 human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not
606 associated with protection. *Cell.* 2021;184(7):1858-64 e10.
- 607 35. Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J, et al. Cross-reactive antibody against
608 human coronavirus OC43 spike protein correlates with disease severity in COVID-19
609 patients: a retrospective study. *Emerg Microbes Infect.* 2021;10(1):664-76.
- 610 36. Renk H, Dulovic A, Seidel A, Becker M, Fabricius D, Zernickel M, et al. Robust and
611 durable serological response following pediatric SARS-CoV-2 infection. *Nat Commun.*
612 2022;13(1):128.
- 613 37. Wong LSY, Loo EXL, Huang CH, Yap GC, Tay MJY, Chua RXY, et al. Early seasonal
614 coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies. *J*
615 *Infect.* 2023;86(1):e10-e2.
- 616 38. Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA
617 vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2
618 infection. *Science.* 2021;372(6549):1413-8.
- 619 39. Zou J, Xia H, Xie X, Kurhade C, Machado RR, Weaver SC, et al. Neutralization against
620 Omicron SARS-CoV-2 from previous non-Omicron infection. *Nature communications.*
621 2022;13(1):852.
- 622 40. Goga A, Bekker LG, Garrett N, Reddy T, Yende-Zuma N, Fairall L, et al. Breakthrough
623 SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa.
624 *Lancet.* 2022;400(10348):269-71.
- 625 41. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. Neutralization against
626 BA. 2.75. 2, BQ. 1.1, and XBB from mRNA Bivalent Booster. *New England Journal of*
627 *Medicine.* 2023;388(2):183-5.
- 628 42. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in
629 immune responses that underlie COVID-19 disease outcomes. *Nature.*
630 2020;588(7837):315-20.
- 631 43. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, and Klein SL. Considering how biological
632 sex impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol.*
633 2020;20(7):442-7.
- 634 44. Pradhan A, and Olsson PE. Sex differences in severity and mortality from COVID-19: are
635 males more vulnerable? *Biol Sex Differ.* 2020;11(1):53.
- 636 45. Gomez JMD, Du-Fay-de-Lavallaz JM, Fugar S, Sarau A, Simmons JA, Clark B, et al. Sex
637 differences in COVID-19 hospitalization and mortality. *Journal of Women's health.*
638 2021;30(5):646-53.

- 639 46. Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. Infection-
640 and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2
641 variant. *Cell Host Microbe*. 2021;29(4):516-21 e3.
- 642 47. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An Infectious
643 cDNA Clone of SARS-CoV-2. *Cell Host Microbe*. 2020;27(5):841-8 e3.
- 644 48. Edara V-V, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and
645 vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B. 1.617 variants.
646 *New England Journal of Medicine*. 2021;385(7):664-6.
- 647 49. Kumar S, Patel A, Lai L, Chakravarthy C, Valanparambil R, Reddy ES, et al. Structural
648 insights for neutralization of Omicron variants BA. 1, BA. 2, BA. 4, and BA. 5 by a broadly
649 neutralizing SARS-CoV-2 antibody. *Science Advances*. 2022;8(40):eadd2032.
- 650 50. Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, et al.
651 Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-
652 CoV-2 Neutralizing Antibodies. *Curr Protoc Immunol*. 2020;131(1):e116.

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669 **Table 1: Cohort demographics**

		Infants/young children	Adults
Sex	Females (%)	13 (57%)	10 (53%)
	Males (%)	10 (43%)	9 (47%)
Median age (range)		249 d (40 – 1441 d)	54 y (20 – 77 y)
Samples collected		February 2020 – April 2022	May 2020 – March 2021
COVID-19 infection		April 2020 – January 2022	March 2020 – April 2020
Patients requiring hospitalization		None (0 %)	3 (16 %)
Severe symptoms		None (0 %)	None (0 %)

670

671

672

673

674

675

676

677

678

679


680

681

682

683

SARS-CoV-2



684


685 **Figure 1: Infants/young children generate durable antibody responses to SARS-CoV-2**
686 **antigens following infection.** IgG (A – C), and IgA (D – F) antibodies reactive to SARS-CoV-2
687 spike (A, D); spike receptor binding domain (RBD) (B, E); and the spike N-terminal domain
688 (NTD) (C, F) were measured in duplicate by an electrochemiluminescent multiplex
689 immunoassay and reported as arbitrary units per ml (AU/mL) as normalized by a standard curve.
690 Longitudinal antibody titers of SARS-Co-2 infected infants/young children (n = 23) are plotted
691 over days post positive PCR result. The dotted line represents the limit of detection, defined as
692 the mean value pre-infection + 3SD.

693


694

695

696



697 **Figure 2: Longitudinal antibody responses against other coronavirus spike proteins in**
698 **infants and their correlation to SARS-CoV-2 spike binding antibody response.**
699 IgG antibodies reactive to the (A) previous epidemic coronaviruses, MERS-CoV and SARS-
700 CoV-1 spike protein, and (B) common human beta-coronaviruses, HKU1 and OC43 spike
701 protein were measured in duplicate by an electrochemiluminescent multiplex immunoassay and
702 reported as arbitrary units per ml (AU/mL) as normalized by a standard curve. Longitudinal
703 antibody titers of SARS-CoV-2 infected infants/young children (n = 23) are plotted over days
704 since the positive PCR result. (C) Pre- SARS-CoV-2 infection IgG binding antibody titers
705 against the spike proteins of currently circulating human beta coronavirus, HKU1 and OC43,
706 showed no correlation with the convalescent titers against SARS-CoV-2 spike in infants/young
707 children. Coefficient of determination (R²), and significance were determined by linear
708 regression analysis.



709

710 **Figure 3: Durability of SARS-CoV-2 spike- and nucleocapsid-binding antibody responses**
711 **in infants/young children and adults.**

712 IgG antibodies reactive to SARS-CoV-2 spike (A, E); spike RBD (B, F); spike NTD (C, G); and
713 nucleocapsid (D, H) were measured in duplicate by an electrochemiluminescent multiplex
714 immunoassay in infants/young children (A – D), and adult (E – H) donors and reported as
715 arbitrary units per ml (AU/mL) as normalized by a standard curve. The half-lives and decay
716 curves of the IgG antibodies estimated by the exponential model are shown in red; and the half-
717 lives and decay curves of IgG antibodies estimated by the power law model (at day 150) are
718 shown in blue.
719

720

721

722

723


724

725

726

727

728



729

730 **Figure 4: Anti-spike IgG subclass distribution in infants/young children and adults.**

731 The concentration of anti-spike IgG subclasses was measured at an early (30 – 140 days post
732 infection, red) and late (250 – 375 days post infection, blue) time points. (A) Early and late time
733 point samples from the infant and adult donors chosen to assess the antibody subclass
734 distribution. (B) Concentration (ug/mL) of anti-spike IgG1, IgG2, IgG3 and IgG4 antibodies at
735 early and late time points in infants and adults. Statistics were calculated using two-tailed Mann-
736 Whitney test. ns – not significant, * $p < 0.05$, ** $p < 0.01$.


737

738

739


740

741



742
 743 **Figure 5: Neutralizing antibody responses against WT SARS-CoV-2 spike in infants/young**
 744 **children and adults.** (A) Neutralizing antibody titers against WT SARS-CoV-2 at early and late
 745 time points in infants and adult donors. (B) SARS-CoV-2 spike and RBD reactive IgG (AU/mL)
 746 levels correlated with the neutralization titers at matched timepoints for infant and adult donors.
 747 The dotted line (A) represents the limit of detection at 1/20. The comparison between groups
 748 were performed using unpaired two-tailed t-test (A). The correlation analyses were performed
 749 using simple linear regression and coefficient of determination (R^2) and significance were
 750 determined (B). ns – not significant, * $p < 0.05$.

751
 752
 753
 754
 755
 756
 757
 758
 759



760
 761 **Figure 6: IgG binding and neutralizing antibody titers against WT, Beta, Delta and**
 762 **Omicron (BA.1) SARS-CoV-2 RBD in infant and adult donors.** Infants exhibit similar
 763 breadth against VOCs as adults. (A) IgG binding to RBD and (B) neutralizing antibody titers
 764 (FRNT50) were analyzed against a panel of VOCs including WT, beta, delta and omicron
 765 (BA.1). The dotted line represents the limit of detection at 1/20 (B). Both infants' and adults'
 766 plasma samples were compared at early and late time points and fold change was calculated as
 767 variant binding (A) or neutralization (B) compared to WT.

